News
Official press releases and latest news
Excision BioTherapeutics
October 2023
Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT-101 for the Treatment of HIV at ESGCT 30th Annual Congress
Excision BioTherapeutics
October 2023
Excision Announces Presentation of Interim Clinical Data at Upcoming ESGCT Annual Congress
Excision BioTherapeutics
August 2023
Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1
Excision BioTherapeutics
July 2023
Excision BioTherapeutics Receives FDA Fast Track Designation for EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1
Excision BioTherapeutics
June 2023
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
Excision BioTherapeutics
October 2022
Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure
Excision BioTherapeutics
September 2022
Excision BioTherapeutics Awarded California Institute for Regenerative Medicine Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Excision BioTherapeutics
September 2022
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Excision BioTherapeutics
September 2022
Excision BioTherapeutics to Present at Upcoming Conferences
Excision BioTherapeutics
June 2022
Excision CEO Daniel Dornbusch Presents at Jefferies Healthcare Conference 2022
Excision BioTherapeutics
May 2022
Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
GLOBE NEWSWIRE
January 2022
Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
GLOBE NEWSWIRE
October 2021
Excision BioTherapeutics Expands Management Team with Three Key Appointments
GLOBE NEWSWIRE
September 2021
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
Temple University
August 2021
Temple Researchers Awarded Prestigious Grant from the NIH’s Martin Delaney Collaboratories for HIV Cure Research Program
GLOBE NEWSWIRE
August 2021
Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
GLOBE NEWSWIRE
JULY 2021
Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer
GLOBE NEWSWIRE
MAY 2021
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine
GLOBE NEWSWIRE
MAY 2021
Excision BioTherapeutics Appoints Biotech Development and Manufacturing Veteran, Franz Gerner, Ph.D., as CTO & Head of Manufacturing
PRESS RELEASE
MAY 2021
Excision BioTherapeutics Adds Gene Therapy Expert Nicole Paulk, Ph.D., to its Scientific Advisory Board
PRESS RELEASE
MAY 2021
Excision BioTherapeutics Appoints Seasoned Finance Executive Christine Silverstein as Chief Financial Officer
GLOBE NEWSWIRE
APR 2021
Excision BioTherapeutics Appoints Biotech Industry R&D Veteran, William Kennedy, M.D., as Senior Vice President, Clinical
ENDPOINTS NEWS
FEB 2021
Exclusive: After four decades, one researcher's radical HIV cure finally gets its shot
GLOBE NEWSWIRE
FEB 2021
Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs
MANAGED HEALTHCARE EXECUTIVE
JAN 2021
CRISPR Gene-Editing Shows Promise Against HIV
​
​
​
​
GEN ENGINEERING & BIOTECH NEWS
DEC 2020
Gene Editing Startups Cut Fine Therapeutic Figures
​
​
​
​
PRESS RELEASE
NOV 2020
CRISPR-Focused Excision BioTherapeutics Announces Business Advisory Board and Addition of Interim Chief Business Officer
PRESS RELEASE
AUG 2020
Excision BioTherapeutics Appoints Veteran Genome Editing Expert
​
​
PRESS RELEASE
JUL 2020
Excision BioTherapeutics to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit
FIERCE BIOTECH
JUN 2020
Biopharma tackles COVID-19, HIV and other viruses with gene and cell therapies
NATURE BRIEFING
MAY 2020
Gene-Editing Pipeline Takes Off
--
Clinical trials of genome-editing agents are pushing ex vivo, immuno-oncology and in vivo treatment frontiers.
PRESS RELEASE
MAR 2020
Excision BioTherapeutics Announces Data Presentation at CROI from IND-Enabling Non-Human Primate studies of EBT-001, supporting a CRISPR Gene Editing Technology for HIV Elimination
PRESS RELEASE
DEC 2019
CRISPR-focused Excision Bio Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, M.D.
​
​
​
PRESS RELEASE
NOV 2019
CRISPR Gene Editing Eliminates Herpes Simplex Virus and JC Virus, Demonstrating Feasibility of a Potential Functional Cure
PRESS RELEASE
NOV 2019
Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology
​
​
PRESS RELEASE
JUL 2019
HIV Eliminated from the Genomes of Living Animals; Excision BioTherapeutics Advancing the Innovation to Clinical Development
WASHINGTON POST
JUL 2019
Scientists say they found a cure for HIV in some mice. Humans could be next
PRESS RELEASE
NOV 2017
Excision BioTherapeutics Exclusively Licenses New CRISPR-Cas Gene Editors from UC Berkeley to be Used for Viral Infections
PRESS RELEASE
SEP 2017
HIV Cure-Focused Excision BioTherapeutics Secures $10 Million in Seed Funding Led by ARTIS Ventures
PRESS RELEASE
MAR 2016